

India

Overweight (no change)

Highlighted Companies
Indoco Remedies Ltd
ADD, TP Rs561, Rs446 close

We expect strong domestic formulations growth led by the pick up in key therapies. We expect Europe sales to remain strong due to its German tender business, while the US may post flattish growth.

Ipsca Laboratories Ltd
ADD, TP Rs2401, Rs2358 close

We expect the domestic business to post strong growth led by the pain, cardiac and anti-infectives portfolios. We expect export formulations to have a muted quarter due to the high base effect.

JB Chemicals & Pharmaceuticals Ltd
ADD, TP Rs2105, Rs1836 close

We expect the domestic business to remain strong yoy but decline qoq on the high base effect in 1QFY22 due to higher Covid influence drugs. We expect flattish international business growth after adjusting for deferred sales of Rs540m in 2QFY21.

Summary Valuation Metrics

P/E (x)	Mar21-A	Mar22-F	Mar23-F
Indoco Remedies Ltd	44.21	26.76	17.67
Ipsca Laboratories Ltd	26.16	27.61	23.57
JB Chemicals & Pharmaceuticals Ltd	31.68	28.66	24.51

P/BV (x)	Mar21-A	Mar22-F	Mar23-F
Indoco Remedies Ltd	5.35	4.57	3.79
Ipsca Laboratories Ltd	6.36	5.26	4.37
JB Chemicals & Pharmaceuticals Ltd	7.84	6.51	5.43

Dividend Yield	Mar21-A	Mar22-F	Mar23-F
Indoco Remedies Ltd	0.34%	0.56%	1.13%
Ipsca Laboratories Ltd	0.34%	0.33%	0.38%
JB Chemicals & Pharmaceuticals Ltd	0.9%	0.87%	1.02%

Analyst(s)

Rashmi SANCHETI

T (91) 22 4161 1549

E rashmi.sancheti@incredcapital.com

Suraj UNADKAT

T (91) 22 4161 1552

E suraj.unadkat@incredcapital.com

Pharmaceuticals

Pharma 2QFY22F preview

- We expect the domestic formulations business of our coverage universe to grow by 11.4% yoy and US formulations to decline by 8.1% yoy in 2QFY22F.
- Higher raw material costs and normalisation of operating expenses could impact EBITDA margins on a yoy basis for our coverage universe in 2QFY22F.
- We expect our pharma coverage universe to report sales growth of 1.7% yoy, but EBITDA/PAT to decline by 10.9%/15.7% yoy in 2QFY22F.

Strong acute season and chronic sales to drive domestic business

We expect 11.4% yoy growth in the domestic formulations business across our pharma coverage universe due to strong acute season and momentum in the chronic portfolio. Contributions from the Covid-19 portfolio are likely to taper off due to the declining number of positive cases in India. According to All Indian Origin Chemists & Distributors Ltd. (AIOCD), the Indian pharmaceuticals market (IPM) grew 14.6% in 2QFY22 led by volume growth of 6.3%, price growth of 5.8% and new products growth of 2.5%. Therapies such as anti-infectives, gastro and pain gained momentum. From our coverage universe, we expect strong domestic formulations performances from JB Chemicals (23.1%), Indoco Remedies (18%) and Alkem Labs (17%).

Price erosion and incremental competition to impact US business

We expect the US formulations business of our coverage universe to decline by 8.1% due to price erosion and incremental competition in base business. From our coverage universe, we believe Cipla would benefit from market share gain in gAlbuterol and gBrovana, Dr Reddy's from market share gain in gVascepa and gKuvan, and Alkem from the limited competition launch of Duexis. However, we expect Cadila to be impacted by the lower offtake of Asacol HD, and Alembic by competition in theophylline.

Expect strong 2Q performance by IPCA, JB Chemicals and Indoco

We expect relatively strong 2QFY22F performance by a) JB Chemicals, led by solid domestic business performance, b) Indoco Remedies, with traction in its anti-infectives, stomatologicals and respiratory portfolio as well as strong German tender business, and c) Ipsca Labs, with momentum in its pain, cardiac and anti-infectives therapies.

We maintain our Overweight rating on the sector

We remain Overweight on the sector given strong domestic pharma market revenue growth, the US business to see differentiated products with strong cash flows fueled by prospective niche launches, and Covid treatment + vaccines across geographies – all of which augur well for industry sales growth. Our top picks are Dr Reddy's, Cipla, Natco, JB Chemicals, Aarti Drugs and Indoco Remedies. Key catalysts: Higher generics prices in the US and rupee depreciation. Key risks: Adverse currency movement, continued price erosion in the US, further increase in input costs and any potential third wave of Covid-19 infections.

Figure 1: 2QFY22F estimates of our coverage universe

Company (Rsm)	Revenue	YoY %	QoQ %	EBITDA	YoY %	QoQ %	PAT	YoY %	QoQ %
Dr. Reddy's Laboratories	51,052	4.3	3.8	10,925	-10.6	21.1	6,747	-19.7	18.2
Cipla	51,201	3.0	-6.4	11,494	-2.3	-14.6	6,702	0.7	-20.1
Torrent Pharmaceuticals	21,263	5.4	-0.4	6,336	-0.2	-6.4	3,009	-2.9	-8.8
Cadila Healthcare	36,105	-5.8	-9.1	7,907	-10.0	-10.7	4,380	-25.2	-17.9
Alkem Laboratories	26,482	12.1	-3.0	5,535	-7.8	-6.6	4,301	-8.9	-8.1
Ipsca Laboratories	14,896	9.4	-4.9	3,650	6.4	-11.6	2,698	6.7	-11.2
Alembic Pharmaceuticals	13,236	-9.2	-0.2	2,343	-47.2	-0.7	1,633	-51.0	-0.7
Natco Pharma	4,267	-46.8	4.0	1,148	-58.5	4.6	738	-63.5	-1.6
Ajanta Pharma	7,690	7.4	2.8	2,288	-16.6	3.9	1,585	-6.9	-8.8
JB Chemicals & Pharmaceuticals	5,500	24.0	-9.2	1,441	30.9	-12.0	1,040	40.9	-12.5
Aarti Drugs	5,826	0.8	0.4	902	-22.5	13.2	559	-25.8	14.5
Granules India	9,122	6.3	7.3	2,217	-13.5	10.1	1,391	-15.0	15.7
Indoco Remedies	3,784	15.3	-2.2	779	28.3	-10.4	355	38.7	-10.6

SOURCES: INCRED RESEARCH ESTIMATES, COMPANY REPORTS

Figure 2: 2QFY22F earnings preview of our coverage universe

Company	2QFY22F	2QFY21	yoy %	1QFY21	qoq %	Comments
Dr Reddy's Laboratories						
Revenue (Rsm)	51,052	48,967	4.3	49,194	3.8	We expect sales growth to be muted despite receiving licensing income. US sales to remain flat due to price erosion and high base of last year, offset by market share ramp up in products like gKuvan and gVascepa.
EBITDA (Rsm)	10,925	12,215	-10.6	9,025	21.1	
EBITDA margin %	21.4	24.9	-350bp	18.3	310bp	
PAT (Rsm)	6,747	8,404	-19.7	5,708	18.2	
PAT (Rsm)	6,747	8,404	-19.7	5,708	18.2	
Cipla Ltd						
Revenue (Rsm)	51,201	49,726	3.0	54,707	-6.4	We expect Cipla to have a muted performance in 2Q. Its India business may remain flat on high base due to higher contribution from the Covid portfolio in the last corresponding quarter. We expect the US base business to be impacted by price erosion, offset by market share gains in gAlbuterol and gBrovana. We expect EBITDA margin to contract by 220bp qoq mainly on account of US pricing pressure and lower domestic sales.
EBITDA (Rsm)	11,494	11,766	-2.3	13,459	-14.6	
EBITDA margin %	22.3	23.4	-110bp	24.5	-220bp	
PAT (Rsm)	6,702	6,654	0.7	8,393	-20.1	
PAT (Rsm)	6,702	6,654	0.7	8,393	-20.1	
Torrent Pharmaceuticals						
Revenue (Rsm)	21,263	20,170	5.4	21,340	-0.4	We expect the India business to benefit from recovery in the chronic portfolio and higher acute sales. We expect US sales to decline due to absence of new launches impacted by the warning letter at Indrad, official action initiated (OAI) at the Dahej facility, and discontinuation of the sartans products. We expect EBITDA margin to decline 170bp yoy with normalisation of operating cost as marketing and field force expenses have come back on a yoy basis.
EBITDA (Rsm)	6,336	6,350	-0.2	6,770	-6.4	
EBITDA margin %	29.8	31.5	-170bp	31.7	-190bp	
PAT (Rsm)	3,009	3,100	-2.9	3,300	-8.8	
PAT (Rsm)	3,009	3,100	-2.9	3,300	-8.8	
Cadila Healthcare						
Revenue (Rsm)	36,105	38,326	-5.8	39,727	-9.1	We expect sales to decline as the US business is likely to be impacted by price erosion, lower offtake of the product Asacol HD, and the disposal of the animal healthcare business. However, we expect India sales growth to be strong with the recovery in its anti-infective and specialty portfolios.
EBITDA (Rsm)	7,907	8,786	-10.0	8,850	-10.7	
EBITDA margin %	21.9	22.9	-100bp	22.3	-40bp	
PAT (Rsm)	4,380	5,852	-25.2	5,334	-17.9	
PAT (Rsm)	4,380	5,852	-25.2	5,334	-17.9	
Alkem Laboratories						
Revenue (Rsm)	26,482	23,628	12.1	27,314	-3.0	We expect the India business to show robust performance from acute therapeutic areas of anti-infectives, gastro, pain and vitamins. We expect the US business to remain flattish due to price erosion in the base business offset by the limited competition launch of the product gDuexis and other launches. We expect EBITDA margin to contract by 460bp yoy on the back of increased raw material prices and uptick in promotional and field expenses.
EBITDA (Rsm)	5,535	6,005	-7.8	5,929	-6.6	
EBITDA margin %	20.9	25.4	-450bp	21.7	-80bp	
PAT (Rsm)	4,301	4,721	-8.9	4,681	-8.1	
PAT (Rsm)	4,301	4,721	-8.9	4,681	-8.1	
Ipca Laboratories						
Revenue (Rsm)	14,896	13,611	9.4	15,658	-4.9	We expect the domestic business to show strong yoy growth mainly led by strong growth in pain, cardiac and anti-infectives therapies. We expect export formulations to have a muted quarter due to the high base effect. We expect EBITDA margin to contract yoy due to lower export formulations sales and high raw material prices.
EBITDA (Rsm)	3,650	3,431	6.4	4,131	-11.6	
EBITDA margin %	24.5	25.2	-70bp	26.4	-190bp	
PAT (Rsm)	2,698	2,528	6.7	3,038	-11.2	
PAT (Rsm)	2,698	2,528	6.7	3,038	-11.2	
Alembic Pharma						
Revenue (Rsm)	13,236	14,571	-9.2	13,260	-0.2	We expect the domestic formulations business to show recovery in the acute business while the US business could decline mainly due to continued price erosion, market share loss in the sartans portfolio and incremental competition in theophylline. We expect EBITDA margin to contract yoy due to the uptick in promotional and field expenses.
EBITDA (Rsm)	2,343	4,434	-47.2	2,359	-0.7	
EBITDA margin %	17.7	30.4	-1270bp	17.8	-10bp	
PAT (Rsm)	1,633	3,334	-51.0	1,645	-0.7	
PAT (Rsm)	1,633	3,334	-51.0	1,645	-0.7	
Natco Pharma						
Revenue (Rsm)	4,267	8,022	-46.8	4,103	4.0	We expect domestic business sales to recover driven by the pick-up in the oncology business and contribution from the Covid portfolio. We expect the US business to be impacted by increased competition in gDoxil and the high base. The EBITDA margin could be impacted by lower sales.
EBITDA (Rsm)	1,148	2,764	-58.5	1,098	4.6	
EBITDA margin %	26.9	34.5	-760bp	26.8	10bp	
PAT (Rsm)	738	2,024	-63.5	750	-1.6	
PAT (Rsm)	738	2,024	-63.5	750	-1.6	
Ajanta Pharma						
Revenue (Rsm)	7,690	7,159	7.4	7,480	2.8	We expect the domestic business to recover and show strong growth led by recovery in the cardiac, derma, ophthal and pain portfolios. We expect the US business to benefit from new product launches offset by base business price erosion. We expect the EBITDA margin to contract yoy on the back of higher raw material prices and increase in promotional and field expenses with normalisation of cost.
EBITDA (Rsm)	2,288	2,743	-16.6	2,202	3.9	
EBITDA margin %	29.8	38.3	-850bp	29.4	40bp	
PAT (Rsm)	1,585	1,702	-6.9	1,738	-8.8	
PAT (Rsm)	1,585	1,702	-6.9	1,738	-8.8	
JB Chemicals & Pharmaceuticals						
Revenue (Rsm)	5,500	4,436	24.0	6,060	-9.2	We expect domestic business to remain strong yoy, while it may decline qoq on account of high base in 1QFY22 due to higher Covid influence drugs. We expect international business growth to optically look higher on low base as sales worth Rs540m were deferred from 2QFY21 to 3QFY21. Adjusting this, we expect flattish growth in the international business in 2QFY22F.
EBITDA (Rsm)	1,441	1,101	30.9	1,637	-12.0	
EBITDA margin %	26.2	24.8	140bp	27.0	-80bp	
PAT (Rsm)	1,040	738	40.9	1,189	-12.5	
PAT (Rsm)	1,040	738	40.9	1,189	-12.5	
Aarti Drugs						
Revenue (Rsm)	5,826	5,781	0.8	5,800	0.4	We expect sales of the API, specialty chemicals and intermediates businesses to remain flat yoy due to the high base effect, while that of the formulations business is expected to show good growth. We expect the EBITDA margin to contract yoy due to contraction in gross margin as a result of higher raw material prices, but expect it show some improvement sequentially.
EBITDA (Rsm)	902	1,164	-22.5	797	13.2	
EBITDA margin %	15.5	20.1	-460bp	13.7	180bp	
PAT (Rsm)	559	753	-25.8	488	14.5	
PAT (Rsm)	559	753	-25.8	488	14.5	
Granules India						
Revenue (Rsm)	9,122	8,581	6.3	8,498	7.3	We expect total revenue to grow by 6.3% due to high base. We expect the Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFI) business to report flat yoy growth, while the Finished Dosages (FD) business is expected to be strong due to new product launches. We expect EBITDA margin to decline due to contraction in gross margin yoy due to higher input cost.
EBITDA (Rsm)	2,217	2,564	-13.5	2,014	10.1	
EBITDA margin %	24	30	-560bp	24	60bp	
PAT (Rsm)	1,391	1,636	-15	1,202	16	
PAT (Rsm)	1,391	1,636	-15	1,202	16	
Indoco Remedies						
Revenue (Rsm)	3,784	3,282	15.3	3,868	-2.2	We expect a strong domestic formulations growth-led pick up in the anti-infectives, stomatological and respiratory portfolios. We expect Europe sales growth to remain strong due to the German tender business and the US business to post flattish growth.
EBITDA (Rsm)	779	607	28.3	869	-10.4	
EBITDA margin %	20.6	18.5	210bp	22.5	-190bp	
PAT (Rsm)	355	256	38.7	397	-10.6	
PAT (Rsm)	355	256	38.7	397	-10.6	


SOURCES: INCRED RESEARCH ESTIMATES, COMPANY REPORTS

Figure 3: No. of ANDA approvals received by our coverage universe during 2QFY22

Company	No. of approvals
Dr. Reddy's Laboratories	3
Cipla	1
Torrent Pharmaceuticals	1
Cadila Healthcare	8
Alkem Laboratories	11
Alembic Pharmaceuticals	3
Ajanta Pharma	2
Granules India	1


SOURCES: INCRED RESEARCH, BLOOMBERG, US FOOD AND DRUG ADMINISTRATION (USFDA)

Figure 4: No. of ANDA approvals for companies globally has declined slightly



SOURCES: INCRED RESEARCH, USFDA

Figure 5: Oral drug shortage declined slightly in 2QCY21 (nos)



SOURCES: INCRED RESEARCH, ASHP.ORG

Figure 6: US formulation revenues of our coverage universe to be impacted by price erosion and incremental competition in base business

Company (Rsm)	2QFY22F	2QFY21	yoy %	1QFY22	qoq %
Dr. Reddy's Laboratories	18,130	18,328	-1.1	17,390	4.3
Cipla	10,360	10,490	-1.2	10,380	-0.2
Torrent Pharmaceuticals	2,590	3,270	-20.8	2,660	-2.6
Cadila Healthcare	15,096	17,090	-11.7	14,514	4.0
Alkem Laboratories	6,290	6,258	0.5	6,043	4.1
Alembic Pharmaceuticals	3,552	5,820	-39.0	3,690	-3.7
Ajanta Pharma	1,663	1,540	8.0	1,680	-1.0
Indoco Remedies	447	434	3.0	462	-3.2

SOURCES: INCRED RESEARCH ESTIMATES, COMPANY REPORTS

Figure 7: Recovery in acute segment and strong chronic portfolio to drive domestic formulations business

Company (Rsm)	2QFY22F	2QFY21	yoy %	1QFY22	qoq %
Dr. Reddy's Laboratories	10,309	9,123	13.0	10,600	-2.7
Cipla	21,318	20,900	2.0	27,100	-21.3
Torrent Pharmaceuticals	10,882	9,630	13.0	10,930	-0.4
Cadila Healthcare	12,174	10,870	12.0	13,566	-10.3
Alkem Laboratories	18,222	15,574	17.0	19,097	-4.6
Ipca Laboratories	6,212	5,355	16.0	6,130	1.3
Alembic Pharmaceuticals	4,690	4,150	13.0	4,810	-2.5
Ajanta Pharma	2,303	2,020	14.0	2,290	0.6
JB Chemicals & Pharmaceuticals	2,630	2,137	23.1	3,130	-16.0
Indoco Remedies	2,061	1,747	18.0	2,151	-4.2

SOURCES: INCRED RESEARCH ESTIMATES, COMPANY REPORTS

Figure 8: Coverage peer comparison

Company Name	Bloomberg Ticker	Closing Price (Rs)	Target Price (Rs)	Rating	Mkt Cap (US\$ bn)	Revenue CAGR FY21-23F	EPS CAGR FY21-23F	P/E (x)		EV/EBITDA (x)		ROE	
								FY22F	FY23F	FY22F	FY23F	FY22F	FY23F
Dr. Reddy's Laboratories	DRRD IN	4,894	5,496	Add	10.9	10%	13%	29.7	24.7	17.4	14.3	15%	16%
Cipla	CIPLA IN	913	1,164	Add	9.9	11%	22%	27.3	20.7	15.1	12.0	14%	17%
Cadila Healthcare	CDH IN	548	671	Add	7.6	9%	6%	25.2	21.8	15.6	13.3	16%	16%
Torrent Pharmaceuticals	TRP IN	3,169	3,010	Hold	7.1	12%	14%	42.7	33.1	20.7	17.0	20%	24%
Alkem Laboratories	ALKEM IN	3,927	4,101	Add	6.3	15%	15%	26.5	23.0	20.2	17.1	22%	22%
Ipca Laboratories	IPCA IN	2,356	2,401	Add	3.9	11%	7%	27.6	23.6	19.9	16.6	21%	20%
Alembic Pharmaceuticals	ALPM IN	819	942	Hold	2.8	7%	-7%	20.9	15.7	14.3	10.9	14%	17%
Natco Pharma	NTCPH IN	892	1,290	Add	2.2	52%	94%	23.3	9.8	17.3	7.4	16%	32%
Ajanta Pharma	AJP IN	2,302	2,490	Hold	2.6	12%	15%	28.2	23.1	19.6	16.1	22%	22%
JB Chemicals & Pharmaceuticals	JBCP IN	1,837	2,105	Add	1.9	17%	19%	24.5	20.9	18.0	15.4	24%	24%
Granules India	GRAN IN	327	441	Add	1.1	19%	16%	14.5	11.0	9.3	7.1	23%	24%
Aarti Drugs	ARTD IN	623	840	Add	0.8	16%	10%	17.1	13.4	11.2	8.9	28%	29%
Indoco Remedies	INDR IN	447	561	Add	0.5	25%	58%	26.8	17.7	12.9	10.3	18%	23%
Coverage universe average													
								25.7	19.9	16.3	12.8	20%	22%

SOURCES: INCRED RESEARCH ESTIMATES, COMPANY REPORTS, BLOOMBERG. PRICED AS AT 11 OCT 2021

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared for and is distributed by CGS-CIMB, Incred Research Services Private Limited (formerly known as by Earnest Innovation Partners Private Limited (hereinafter referred to as "IRSPL") pursuant to an arrangement between IRSPL and CGS-CIMB. IRSPL is not an affiliate of CGS-CIMB. IRSPL is held 76% by InCred Capital Wealth Portfolio Managers Private Limited and 24% by EIP Holdings Private Limited. IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000007793. Pursuant to a trademark agreement, IRSPL has adopted "InCred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. The term "CGS-CIMB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case except as otherwise stated herein, CGS-CIMB Securities International Pte. Ltd. and its affiliates, subsidiaries and related corporations. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation and remains subject to the "Restrictions on Distribution" set out below. If your status has changed or the distribution restrictions set out below impact your ability to receive this report please contact your usual CGS-CIMB representative.

By accepting this report, the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein (including the "Restrictions on Distributions" set out below). Any failure to comply with these limitations may constitute a violation of law and limit our ability to provide reports to you.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL or CGS-CIMB.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

Under the terms of the agreement between IRSPL and CGS-CIMB, IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. Neither IRSPL nor CGS-CIMB is under any obligation to update this report in the event of a material change to the information contained in this report. Neither IRSPL nor CGS-CIMB has any and will accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies and/or CGS-CIMB, its affiliates and related persons including China Galaxy International Financial Holdings Limited ("CGIFHL") and CIMB Group Sdn. Bhd. ("CIMBG") and their respective related corporations (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof. In particular, CGS-CIMB disclaims all responsibility and liability for the views and opinions set out in this report.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies and/or CGS-CIMB or their respective affiliates (including CGIFHL, CIMBG and their respective related corporations) or IRSPL and its affiliates/group companies, to any person to buy or sell any investments.

By IRSPL producing this report for CGS-CIMB, IRSPL has confirmed to CGS-CIMB that the opinions expressed are based on information it believes to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request.

The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

CGS-CIMB DISCLOSURES

Country	CGS-CIMB Entity	Regulated by
Hong Kong	CGS-CIMB Securities (Hong Kong) Limited	Securities and Futures Commission Hong Kong
India	CGS-CIMB Securities (India) Private Limited	Securities and Exchange Board of India (SEBI)
Indonesia	PT CGS-CIMB Sekuritas Indonesia	Financial Services Authority of Indonesia
Malaysia	CGS-CIMB Securities Sdn. Bhd.	Securities Commission Malaysia
Singapore	CGS-CIMB Securities (Singapore) Pte. Ltd.	Monetary Authority of Singapore
South Korea	CGS-CIMB Securities (Hong Kong) Limited, Korea Branch	Financial Services Commission and Financial Supervisory Service
Thailand	CGS-CIMB Securities (Thailand) Co. Ltd.	Securities and Exchange Commission Thailand

Other Significant Financial Interests:

As of the end of 30th September 2021 immediately preceding the date of this report CGS-CIMB does not:

- have a proprietary position in the securities (which may include but not be limited to shares, warrants, call warrants and/or any other derivatives) in the company(ies) covered in this report except for the following:
 - Nil
- act as market maker or have assumed an underwriting commitment in securities of the company(ies) covered in this report except for the following:
 - Nil
- perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to the company(ies) covered in this report and/or solicit such investment, advisory or other services from the company(ies) covered in this report except for the following:
 - Nil

CGS-CIMB, its affiliates, related corporations (including CGIFHL, CIMBG and their respective related corporations) and/or their respective directors, associates, connected parties and/or employees and/or IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

CGS-CIMB, its affiliates and related corporations (including CGIFHL, CIMBG and their respective related corporations) and/or IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part

This report does not purport to contain all the information that a prospective investor may require. Neither CGS-CIMB nor any of its affiliates (including CGIFHL, CIMBG and their related corporations) make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report. Neither CGS-CIMB nor any of its affiliates nor their related persons (including CGIFHL, CIMBG and their related corporations) shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst CGS-CIMB's and its affiliates' (including CGIFHL's, CIMBG's and their respective related corporations') clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments or any derivative instrument, or any rights pertaining thereto.

Investors are advised to make their own independent evaluation of the information contained in this report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report

Restrictions on Distributions

Australia: Despite anything in this report to the contrary, this research is prepared for and provided in Australia by CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited. This research is only available in Australia to persons who are "wholesale clients" (within the meaning of the Corporations Act 2001 (Cth) and is supplied solely for the use of such wholesale clients and shall not be distributed or passed on to any other person. You represent and warrant that if you are in Australia, you are a "wholesale client". This research is of a general nature only and has been prepared without taking into account the objectives, financial situation or needs of the individual recipient. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited do not hold, and are not required to hold an Australian financial services license. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited rely on "passporting" exemptions for entities appropriately licensed by the Monetary Authority of Singapore (under ASIC Class Order 03/1102) and the Securities and Futures Commission in Hong Kong (under ASIC Class Order 03/1103).

Canada: This report has not been prepared in accordance with the disclosure requirements of Dealer Member Rule 3400 – Research Restrictions and Disclosure Requirements of the Investment Industry Regulatory Organization of Canada. For any research report distributed by CIBC, further disclosures related to CIBC conflicts of interest can be found at <https://researchcentral.cibcwm.com>.

China: For the purpose of this report, the People's Republic of China ("PRC") does not include the Hong Kong Special Administrative Region, the Macau Special Administrative Region or Taiwan. The distributor of this report has not been approved or licensed by the China Securities Regulatory Commission or any other relevant regulatory authority or governmental agency in the PRC. This report contains only marketing information. The distribution of this report is not an offer to buy or sell to any person within or outside PRC or a solicitation to any person within or outside of PRC to buy or sell any instruments described herein. This report is being issued outside the PRC to a limited number of institutional investors and may not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose.

France: Only qualified investors within the meaning of French law shall have access to this report. This report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial instruments and it is not intended as a solicitation for the purchase of any financial instrument.

Germany: This report is only directed at persons who are professional investors as defined in sec 31a(2) of the German Securities Trading Act (WpHG). This publication constitutes research of a non-binding nature on the market situation and the investment instruments cited here at the time of the publication of the information.

The current prices/yields in this issue are based upon closing prices from Bloomberg as of the day preceding publication. Please note that neither the German Federal Financial Supervisory Agency (BaFin), nor any other supervisory authority exercises any control over the content of this report.

Hong Kong: This report is prepared for and distributed in Hong Kong by CGS-CIMB Securities (Hong Kong) Limited ("CHK") which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities) and Type 4 (advising on securities) activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact the Head of Sales at CHK. The views and opinions in this report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CHK has no obligation to update its

opinion or the information in this report.

This publication is strictly confidential and is for private circulation only to clients of CHK.

India: This report is prepared by IRSPL for and distributed in India by IRSPL or CGS-CIMB Securities (India) Private Limited ("CGS-CIMB India"), as the case may be. CGS-CIMB India is a subsidiary of CGS-CIMB Securities International Pte. Ltd. which is in turn is a 50:50 joint venture company of CGIFHL and CIMBG. The details of the members of the group of companies of CGS-CIMB can be found at www.cgs-cimb.com, CGIFHL at www.chinastock.com.hk/en/ACG/ContactUs/index.aspx and CIMBG at www.cimb.com/en/who-we-are.html. CGS-CIMB India is registered with the National Stock Exchange of India Limited and BSE Limited as a trading and clearing member (under the Securities and Exchange Board of India (Stock Brokers and Sub-Brokers) Regulations, 1992). CGS-CIMB India is registered with SEBI (SEBI Registration Number: INZ000209135) as a Research Analyst (INH000000669) pursuant to the SEBI (Research Analysts) Regulations, 2014 ("Regulations").

By IRSPL producing this report for CGS-CIMB, IRSPL has confirmed to CGS-CIMB that the research analysts, strategists or economists principally responsible for the preparation of this report are segregated from the other activities of IRSPL and they have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues, client feedback and competitive factors. Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed or proposed to be performed by IRSPL, CGS-CIMB India or its affiliates.

This report does not take into account the particular investment objectives, financial situations, or needs of the recipients. It is not intended for and does not deal with prohibitions on investment due to law/jurisdiction issues etc. which may exist for certain persons/entities. Recipients should rely on their own investigations and take their own professional advice before investment.

CGS-CIMB India does not have actual / beneficial ownership of 1% or more securities of the subject company in this report, at the end of the month immediately preceding the date of publication of this report. However, since affiliates of CGS-CIMB India are engaged in the financial services business, they might have in their normal course of business financial interests or actual / beneficial ownership of one per cent or more in various companies including the subject company in this report.

CGS-CIMB India or its associates, may: (a) from time to time, have long or short position in, and buy or sell the securities of the subject company in this report; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company in this report or act as an advisor or lender/borrower to such company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

CGS-CIMB India and associates have not received any compensation for investment banking, merchant banking or brokerage services from the subject company mentioned in the report in the past 12 months.

CGS-CIMB India and associates have not managed or co-managed public offering of securities for the subject company mentioned in the report in the past 12 months.

Indonesia: This report is prepared for and distributed in Indonesia by PT CGS-CIMB Sekuritas Indonesia ("CGS-CIMB Indonesia"). The views and opinions in this report is prepared from data believed to be correct and reliable at the time of issue of this report and are subject to change. CGS-CIMB Indonesia has no obligation to update the opinion or the information in this report. This report is for private circulation only to clients of CGS-CIMB Indonesia. Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable Indonesian capital market laws and regulations.

This report is not an offer of securities in Indonesia. The securities referred to in this report have not been registered with the Financial Services Authority (Otoritas Jasa Keuangan) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market law and regulations.

Ireland: CGS-CIMB is not an investment firm authorised in the Republic of Ireland and no part of this document should be construed as CGS-CIMB acting as, or otherwise claiming or representing to be, an investment firm authorised in the Republic of Ireland.

Malaysia: This report is prepared for and distributed in Malaysia by CGS-CIMB Securities Sdn. Bhd. ("CGS-CIMB Malaysia") solely for the benefit of and for the exclusive use of our clients. Recipients of this report are to contact CGS-CIMB Malaysia, at Level 29, Menara Bumiputra-Commerce, No. 11, Jalan Raja Laut, 50350 Kuala Lumpur, Malaysia, in respect of any matters arising from or in connection with this report. CGS-CIMB Malaysia has no obligation to update, revise or reaffirm the opinion or the information in this report after the date of this report.

New Zealand: In New Zealand, this report is for distribution only to persons who are wholesale clients pursuant to section 5C of the Financial Advisers Act 2008.

Singapore: This report is prepared for and distributed in Singapore by CGS-CIMB Securities (Singapore) Pte Ltd ("CGS-CIMB Singapore"). CGS-CIMB Singapore is a capital markets services licensee under the Securities and Futures Act (Chapter 289). Accordingly, it is exempted from the requirement to hold a financial adviser's licence under the Financial Advisers Act, Cap 110 ("FAA") for advising on investment products, by issuing or promulgating research analyses or reports, whether in electronic, print or other form. CGS-CIMB Singapore is subject to the applicable rules under the FAA unless it is able to avail itself to any prescribed exemptions.

Recipients of this report are to contact CGS-CIMB Singapore, 50 Raffles Place, #16-02 Singapore Land Tower, Singapore in respect of any matters arising from, or in connection with this report. CGS-CIMB Singapore has no obligation to update the opinion or the information in this report. This publication is strictly confidential and is for private circulation only. If you have not been sent this report by CGS-CIMB Singapore directly, you may not rely, use or disclose to anyone else this report or its contents.

If the recipient of this report is not an accredited investor, expert investor or institutional investor, CGS-CIMB Singapore accepts legal responsibility for the contents of the report without any disclaimer limiting or otherwise curtailing such legal responsibility. If the recipient is an accredited investor, expert investor or institutional investor, the recipient is deemed to acknowledge that CGS-CIMB Singapore is exempt from certain requirements under the FAA and its attendant regulations, and as such, is exempt from complying with the following:

- (a) Section 25 of the FAA (obligation to disclose product information);
- (b) Section 27 of the FAA (duty not to make recommendation with respect to any investment product without having a reasonable basis where you may be reasonably expected to rely on the recommendation);

- (c) MAS Notice on Information to Clients and Product Information Disclosure [Notice No. FAA-N03];
 (d) MAS Notice on Recommendation on Investment Products [Notice No. FAA-N16];
 (e) Section 36 of the FAA (obligation on disclosure of interest in specified products); and
 (f) any other laws, regulations, notices, directive, guidelines, circulars and practice notes which relates to the above, to the extent permitted by applicable laws, as may be amended from time to time, and any other laws, regulations, notices, directive, guidelines, circulars, and practice notes as we may notify you from time to time. In addition, the recipient who is an accredited investor, expert investor or institutional investor acknowledges that as CGS-CIMB Singapore is exempt from Section 27 of the FAA, the recipient will also not be able to file a civil claim against CGS-CIMB Singapore for any loss or damage arising from the recipient's reliance on any recommendation made by CGS-CIMB Singapore which would otherwise be a right that is available to the recipient under Section 27 of the FAA.

CGS-CIMB Singapore, its affiliates and related corporations, their directors, associates, connected parties and/or employees may own or have positions in specified products of the company(ies) covered in this report or any specified products related thereto and may from time to time add to or dispose of, or may be materially interested in, any such specified products. Further, CGS-CIMB Singapore, its affiliates and its related corporations do and seek to do business with the company(ies) covered in this report and may from time to time act as market maker or have assumed an underwriting commitment in specified products of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

As of CGS-CIMB Singapore does not have a proprietary position in the recommended specified products in this report.

CGS-CIMB Singapore makes a market on the specified products.

CGS-CIMB Singapore does not make a market on other specified products mentioned in the report.

South Korea: This report is prepared for and distributed in South Korea by CGS-CIMB Securities (Hong Kong) Limited, Korea Branch ("CGS-CIMB Korea") which is licensed as a cash equity broker, and regulated by the Financial Services Commission and Financial Supervisory Service of Korea. In South Korea, this report is for distribution only to professional investors under Article 9(5) of the Financial Investment Services and Capital Market Act of Korea ("FSCMA").

Spain: This document is a research report and it is addressed to institutional investors only. The research report is of a general nature and not personalised and does not constitute investment advice so, as the case may be, the recipient must seek proper advice before adopting any investment decision. This document does not constitute a public offering of securities.

CGS-CIMB is not registered with the Spanish Comision Nacional del Mercado de Valores to provide investment services.

Sweden: This report contains only marketing information and has not been approved by the Swedish Financial Supervisory Authority. The distribution of this report is not an offer to sell to any person in Sweden or a solicitation to any person in Sweden to buy any instruments described herein and may not be forwarded to the public in Sweden.

Switzerland: This report has not been prepared in accordance with the recognized self-regulatory minimal standards for research reports of banks issued by the Swiss Bankers' Association (Directives on the Independence of Financial Research).

Thailand: This report is prepared for and distributed in Thailand by CGS-CIMB Securities (Thailand) Co. Ltd. ("CGS-CIMB Thailand") based upon sources believed to be reliable (but their accuracy, completeness or correctness is not guaranteed). The statements or expressions of opinion herein were arrived at after due and careful consideration for use as information for investment. Such opinions are subject to change without notice and CGS-CIMB Thailand has no obligation to update its opinion or the information in this report.

CGS-CIMB Thailand may act or acts as Market Maker, and issuer and offerer of Derivative Warrants and Structured Note which may have the following securities as its underlying securities. Investors should carefully read and study the details of the derivative warrants in the prospectus before making investment decisions.

AAV, ACE, ADVANC, AEONTS, AMATA, AOT, AP, BAM, BANPU, BBL, BCH, BCP, BCPG, BDMS, BEC, BEM, BGRIM, BH, BJC, BTS, CBG, CENTEL, CHG, CK, CKP, COM7, CPALL, CPF, CPN, CRC, DELTA, DOHOME, DTAC, EA, EGCO, ESSO, GLOBAL, GPSC, GULF, GUNKUL, HANA, HMPRO, ICHI, INTUCH, IRPC, IVL, JAS, JMART, JMT, KBANK, KCE, KKP, KTB, KTC, LH, MAJOR, MEGA, MINT, MTC, NRF, OR, ORI, OSP, PLANB, PRM, PSL, PTG, PTL, PTT, PTTEP, PTTGC, QH, RATCH, RBF, RS, SAWAD, SCB, SCC, SCGP, SINGER, SPALI, SPRC, STA, STEC, STGT, SUPER, SYNEX, TASCOS, TCAP, THANI, TISCO, TKN, TOP, TQM, TRUE, TTB, TU, TVO, VGI, WHA

Corporate Governance Report:

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. CGS-CIMB Thailand does not confirm nor certify the accuracy of such survey result.

Score Range:	90 - 100	80 – 89	70 - 79	Below 70	No Survey Result
Description:	Excellent	Very Good	Good	N/A	N/A

United Arab Emirates: The distributor of this report has not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities or governmental agencies in the United Arab Emirates. This report is strictly private and confidential and has not been reviewed by, deposited or registered with UAE Central Bank or any other licensing authority or governmental agencies in the United Arab Emirates. This report is being issued outside the United Arab Emirates to a limited number of institutional investors and must not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose. Further, the information contained in this report is not intended to lead to the sale of investments under any subscription agreement or the conclusion of any other contract of whatsoever nature within the territory of the United Arab Emirates.

United Kingdom and European Economic Area (EEA): In the United Kingdom and European Economic Area, this material is prepared for and being distributed by CGS-CIMB Securities (UK) Limited ("CGS-CIMB UK"). CGS-CIMB UK is authorized and regulated by the Financial Conduct Authority and its registered office is at 27 Knightsbridge, London, SW1X7YB. The material distributed by CGS-CIMB UK has been prepared in accordance with CGS-CIMB's policies for managing conflicts of interest arising as a result of publication and distribution of this material. This material is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of CGS-CIMB UK; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (c) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order; (d) are outside the United Kingdom subject to relevant regulation in each jurisdiction, material (all such persons together being referred to as "relevant persons"). This material is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

This material is categorised as non-independent for the purposes of CGS-CIMB UK and therefore does not provide an impartial or objective assessment of the subject matter and does not constitute independent research. Consequently, this material has not been prepared in accordance with legal requirements designed to promote the independence of research and will not be subject to any prohibition on dealing ahead of the dissemination of research. Therefore, this material is considered a marketing communication.

United States: This report is prepared for and distributed in the United States of America by CGS-CIMB Securities (USA) Inc, a U.S. registered broker-dealer and an affiliate of CGS-CIMB Securities Sdn. Bhd., CGS-CIMB Securities (Singapore) Pte Ltd, PT CGS-CIMB Sekuritas Indonesia, CGS-CIMB Securities (Thailand) Co. Ltd, CGS-CIMB Securities (Hong Kong) Limited and CGS-CIMB Securities (India) Private Limited, and is distributed solely to persons who qualify as "U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934. This communication is only for Institutional Investors whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major Institutional Investor must not rely on this communication. The delivery of this report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. CGS-CIMB Securities (USA) Inc, is a FINRA/SIPC member and takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc.

CGS-CIMB Securities (USA) Inc. has managed or co-managed a public offering of securities in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not managed or co-managed a public offering of any of the securities mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. has received compensation for investment banking services in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not received compensation for investment banking services from any of the company mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. expects to receive or intend to seek compensation for investment banking services within the next 3 months.

CGS-CIMB Securities (USA) Inc. neither expects to receive nor intends to seek compensation for investment banking services from any of the company mentioned within the next 3 months.

As of the end of the month immediately preceding the date of publication of this report, CGS-CIMB Securities (USA) Inc. beneficially owns 1% or more of any class of common equity securities.

United States Third-Party Disclaimer: If this report is distributed in the United States of America by Raymond James & Associates, Inc ("RJA"), this report is third-party research prepared for and distributed in the United States of America by RJA pursuant to an arrangement between RJA and CGS-CIMB Securities International Pte. Ltd. ("CGS-CIMB"). CGS-CIMB is not an affiliate of RJA. This report is distributed solely to persons who qualify as "U.S. Institutional Investors" or as "Major U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934, as amended. This communication is only for U.S. Institutional Investors or Major U.S. Institutional Investor whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major U.S. Institutional Investor must not rely on this communication. The delivery of this report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. If you are receiving this report in the U.S from RJA, a FINRA/SIPC member, it takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc. or RJA. <https://raymondjames.com/InternationalEquityDisclosures>

Other jurisdictions: In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is only for distribution to professional, institutional, or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Corporate Governance Report of Thai Listed Companies (CGR). CG Rating by the Thai Institute of Directors Association (Thai IOD) in 2020, Anti-Corruption 2020

ADVANC – Excellent, Certified, **AMATA** – Excellent, Certified, **ANAN** – Excellent, n/a, **AOT** – Excellent, n/a, **AP** – Excellent, Certified, **ASP** – Excellent, n/a, **AU** – Good, n/a, **BAM** – Very Good, Certified, **BAY** – Excellent, Certified, **BBL** – Very Good, Certified, **BCH** – Good, Certified, **BCP** – Excellent, Certified, **BCPG** – Excellent, Certified, **BDMS** – Excellent, n/a, **BEAUTY** – Good, n/a, **BH** – Good, n/a, **BJC** – Very Good, n/a, **BLA** – Excellent, Certified, **BTS** – Excellent, Certified, **CBG** – Very Good, n/a, **CCET** – n/a, n/a, **CENTEL** – Excellent, Certified, **CHAYO** – Very Good, n/a, **CHG** – Very Good, n/a, **CK** – Excellent, n/a, **COM7** – Very Good, Certified, **CPALL** – Excellent, Certified, **CPF** – Excellent, Certified, **CPN** – Excellent, Certified, **CPNREIT** – n/a, n/a, **CRC** – Very Good, n/a, **DELTA** – Excellent, Certified, **DDD** – Very Good, n/a, **DIF** – n/a, n/a, **DOHOME** – Very Good, n/a, **DREIT** – n/a, n/a, **DTAC** – Excellent, Certified, **ECL** – Excellent, Certified, **EGCO** – Excellent, Certified, **EPG** – Excellent, Certified, **ERW** – Very Good, Certified, **GFPT** – Excellent, Certified, **GGC** – Excellent, Certified, **GLOBAL** – Very Good, n/a, **HANA** – Excellent, Certified, **HMPRO** – Excellent, Certified, **HUMAN** – Good, n/a, **ICHI** – Excellent, Certified, **III** – Excellent, n/a, **INTUCH** – Excellent, Certified, **IRPC** – Excellent, Certified, **ITD** – Very Good, n/a, **IVL** – Excellent, Certified, **JASIF** – n/a, n/a, **JKN** – Excellent, Declared, **JMT** – Very Good, Declared, **KBANK** – Excellent, Certified, **KCE** – Excellent, Certified, **KEX** – n/a, n/a, **KKP** – Excellent, Certified, **KSL** – Excellent, Certified, **KTB** – Excellent, Certified, **KTC** – Excellent, Certified, **LH** – Excellent, n/a, **LPN** – Excellent, Certified, **M** – Very Good, Certified, **MAKRO** – Excellent, Certified, **MC** – Excellent, Certified, **MEGA** – Very Good, n/a, **MINT** – Excellent, Certified, **MTC** – Excellent, Certified, **NETBAY** – Very Good, n/a, **NRF** – n/a, n/a, **OR** – n/a, n/a, **ORI** – Excellent, Certified, **OSP** – Very Good, n/a, **PLANB** – Excellent, Certified, **PRINC** – Very Good, Certified, **PR9** – Excellent, n/a, **PSH** – Excellent, Certified, **PTT** – Excellent, Certified, **PTTEP** – Excellent, Certified, **PTTGC** – Excellent, Certified, **QH** – Excellent, Certified, **RBF** – Good, n/a, **RS** – Excellent, n/a, **RSP** – Good, n/a, **S** – Excellent, n/a, **SAK** – n/a, n/a, **SAPPE** – Very Good, Certified, **SAWAD** – Very Good, n/a, **SCB** – Excellent, Certified, **SCC** – Excellent, Certified, **SCGP** – n/a, n/a, **SHR** – Very Good, n/a, **SIRI** – Excellent, Certified, **SPA** – Very Good, n/a, **SPALI** – Excellent, Declared, **SPRC** – Excellent, Certified, **SSP** – Good, Declared, **STEC** – n/a, n/a, **SVI** – Excellent, Certified, **SYNEX** – Very Good, n/a, **TCAP** – Excellent, Certified, **THANI** – Excellent, Certified, **TIDLOR** – n/a, n/a, **TISCO** – Excellent, Certified, **TKN** – Very Good, n/a, **TMB** – Excellent, Certified, **TOP** – Excellent, Certified, **TRUE** – Excellent, Certified, **TU** – Excellent, Certified, **TVO** – Excellent, Certified, **VGI** – Excellent, Certified, **WHA** – Excellent, Certified, **WHART** – n/a, n/a, **WICE** – Excellent, Certified, **WORK** – Good, n/a.

- CG Score 2020 from Thai Institute of Directors Association (IOD)

- Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of January 30, 2021) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.

Recommendation Framework

Stock Ratings

Definition:

Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.

The total expected return of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net dividend yields of the stock. Stock price targets have an investment horizon of 12 months.

Sector Ratings

Definition:

Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.

Country Ratings

Definition:

Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.